In ovarian cancer, bexarotene induces pyroptosis, depletes total glutathione, represses nuclear factor erythroid 2-related factor 2-dependent transcription, elevates cellular reactive oxygen species, and inhibits protein kinase B phosphorylation [77,78], which further supports the RXR/LXR signaling pathway as a potential therapeutic target in ovarian cancer. The gene discussed is AKT1; the disease is ovarian carcinoma.